Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
As long-acting injectables near approval, daily pill versions of the same drugs show long-term benefit.
Surveys reveal difficulties associated with daily pills and a desire for long-acting injectable therapy.
Recently, ViiV Healthcare applied for approval of the first long-acting injectable HIV regimen.
The experimental long-acting injectable regimen of cabotegravir and rilpivirine stands poised for approval.
Given every four weeks, the combo injection of cabotegravir and Edurant (rilpivirine) will likely face an FDA decision by early 2020.
The trial will investigate whether injections of long-acting cabotegravir and rilpivirine yield a superior rate of viral suppression.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.